|Bid||56.45 x 900|
|Ask||59.16 x 900|
|Day's Range||54.33 - 56.71|
|52 Week Range||27.35 - 59.75|
|Beta (5Y Monthly)||1.25|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 03, 2023 - May 08, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||72.00|
AUSTIN, Texas, March 22, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in Cancer showing the prognostic and predictive utility of Natera’s personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to inform adjuvant treatment decisions and monitor for recurrence and therapy response in patients with stages III-IV melanoma. The full study can be found here.
AUSTIN, Texas, March 02, 2023--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the Company’s first commercial coverage policies for its molecular residual disease test, Signatera, including its first pan-cancer coverage policy for adjuvant, recurrence monitoring, and treatment monitoring.
Natera (NTRA) delivered earnings and revenue surprises of 2.14% and 0.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?